Drugs / Pyrrolitinib
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06470347 | Nov 2022 → Nov 2024 | HER2 positive breast carcinoma | Zunyi Medical College | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05918328 | May 2023 → Dec 2025 overdue | HER2 positive breast carcinoma | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04785729 | Dec 2020 → Dec 2023 | — | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT04508803 | Sep 2020 → Aug 2022 | — | Fudan University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pyrrolitinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06470347 ↗ |
| Route | Oral | “Pyrrolitinib is taken orally at 400mg per day” NCT04508803 ↗ |